Indivior has reached an agreement to settle all outstanding claims over allegations of improper marketing of its opioid use disorder drug Suboxone Film in the US.
UK-based pharma Indivior has agreed a takeover deal with Opiant Pharma that consolidates its position in the addiction treatment category with a new intranasal therapy, due to be filed with
Indivior has failed in its bid to prevent a lawsuit claiming that it illegally blocked competition to opioid addiction drug Suboxone from coming to court in the US.
Indivior has paid out $300 million to resolve civil claims from US states after it was last year found guilty against criminal charges of improper marketing of the opioid addiction drug Sub
UK drugmaker Indivior looks finally to have put years of uncertainty over its exposure to opioid litigation in the US behind it, after agreeing a $600 million settlement.
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio